Does gynaecomastia affect fertility? This is a question many men face when they notice breast tissue enlargement alongside concerns about their reproductive health. Gynaecomastia — the benign enlargement of glandular breast tissue in males — does not directly cause infertility, but the two conditions can share common hormonal roots. Understanding the relationship between gynaecomastia and male fertility is clinically important, as an underlying endocrine disorder may be responsible for both. This article explains the causes, when to seek medical advice, and what diagnostic and treatment options are available within the UK healthcare system.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign enlargement of male glandular breast tissue caused by an oestrogen–androgen imbalance. Common causes include medications, hypogonadism, liver disease, and hormonal tumours; it does not directly cause infertility.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen (testosterone) activity in the body. It is important to distinguish true gynaecomastia — which involves actual glandular tissue — from pseudogynaecomastia, which is caused by excess fatty tissue and is more commonly associated with obesity. Both conditions can cause physical discomfort and psychological distress, but they have different underlying mechanisms.

The condition is surprisingly common across all age groups. It frequently occurs during three key life stages:

• Neonatal period — due to maternal oestrogen crossing the placenta; this typically resolves within a few weeks

• Puberty — when hormonal fluctuations are at their most pronounced; pubertal gynaecomastia often resolves spontaneously within 6–24 months

• Older adulthood — as testosterone levels naturally decline with age

In many cases, gynaecomastia is physiological and resolves without intervention. However, it can also be triggered by a range of identifiable causes, including:

• Medications such as spironolactone, cimetidine, finasteride, bicalutamide, anabolic steroids, antiretrovirals, and some antipsychotics — both prescribed and over-the-counter or herbal products should be reviewed

• Recreational substances including alcohol; cannabis has been reported as a possible associated factor, though the evidence for a direct causal link is limited and not conclusive

• Medical conditions such as hypogonadism, hyperthyroidism, liver cirrhosis, and chronic kidney disease

• Tumours of the testes, adrenal glands, or pituitary gland (less common but clinically significant)

Understanding the root cause is essential, as gynaecomastia itself is generally a symptom rather than a standalone diagnosis. Importantly, the condition does not directly cause infertility in most cases; however, the underlying hormonal imbalances responsible for gynaecomastia may simultaneously affect reproductive function — a distinction that is clinically meaningful and worth exploring further.

Underlying Conditions That May Affect Both

Gynaecomastia and male infertility share common hormonal causes, including hypogonadism, Klinefelter syndrome, and hyperprolactinaemia, all of which can impair spermatogenesis and warrant specialist investigation under NICE NG156.

To answer the question 'does gynaecomastia affect fertility' accurately, it is necessary to look beyond the breast tissue itself and consider the shared hormonal pathways that can influence both. Gynaecomastia and male infertility do not have a direct causal relationship, but they can share common underlying causes — meaning that when one is present, the other may also be a concern.

Hypogonadism is one of the most clinically relevant examples. This condition, characterised by reduced testosterone production from the testes, can lead to both gynaecomastia (due to a relative excess of oestrogen) and impaired spermatogenesis (sperm production), thereby reducing fertility. Hypogonadism may be primary (originating in the testes) or secondary (resulting from dysfunction in the hypothalamic-pituitary axis).

Klinefelter syndrome (47,XXY karyotype) is a genetic condition that frequently presents with gynaecomastia and is one of the most common causes of male infertility in the UK. Men with this condition typically have small, firm testes, low testosterone, and significantly reduced or absent sperm production.

Hyperprolactinaemia — elevated levels of the hormone prolactin, often caused by a pituitary adenoma — can suppress the hypothalamic-pituitary-gonadal axis, reducing testosterone and impairing both libido and sperm production, while also contributing to gynaecomastia.

Other shared risk factors include:

• Liver disease, which impairs oestrogen metabolism

• Anabolic steroid use, which suppresses natural testosterone production and can cause testicular atrophy; recovery of spermatogenesis after stopping anabolic steroids may take many months to over a year

• Obesity, which increases peripheral conversion of androgens to oestrogens via aromatase activity in adipose tissue

In summary, while gynaecomastia itself does not directly impair fertility, its presence — particularly when unexplained — may serve as an important clinical indicator of an underlying hormonal disorder that warrants further investigation. NICE guideline NG156 (Fertility problems: assessment and treatment) provides the UK standard for investigation and referral in cases of male infertility and is the framework within which shared causes should be assessed.

When to Seek Medical Advice from Your GP or Specialist

See your GP if gynaecomastia persists beyond 3–6 months, is painful, or accompanies fertility concerns or testicular changes; urgent 2-week-wait referral is required for features suggesting breast or testicular malignancy.

Many men feel embarrassed to discuss gynaecomastia with a healthcare professional, but early assessment is important — particularly when fertility concerns are also present. Knowing when to seek help can make a significant difference in identifying any treatable underlying cause.

You should contact your GP if you notice:

• Breast tissue enlargement that is persistent (lasting more than 3–6 months), progressive, or causing significant pain or distress

• Breast pain, tenderness, or nipple discharge

• Symptoms of low testosterone, such as reduced libido, fatigue, erectile dysfunction, or reduced body hair

• Testicular changes, including pain, swelling, or altered size or texture

• Difficulty conceiving after 12 months of regular unprotected intercourse (in line with NICE NG156)

Urgent referral — suspected cancer (NICE NG12):

Whilst breast cancer in men is rare, it does occur. Men aged 50 or over with a unilateral, hard subareolar mass — with or without nipple discharge or skin changes — should be referred urgently via the suspected cancer pathway (2-week wait) for specialist assessment. Do not delay seeking advice if you notice these features.

For testicular changes, NICE NG12 recommends an urgent 2-week-wait referral for any non-painful enlargement of the testis or a change in shape or texture. Your GP may also arrange an urgent scrotal ultrasound if a testicular lump is suspected. These features should never be attributed to gynaecomastia alone without proper assessment.

Your GP will take a thorough medical and medication history — including prescribed, over-the-counter, and herbal products — as many commonly used medicines can cause gynaecomastia. They will also conduct a physical examination and arrange initial blood tests.

If an underlying endocrine disorder or fertility concern is identified, referral to an endocrinologist or urologist/andrologist is appropriate. Men with gynaecomastia and concurrent fertility concerns should not assume the two are unrelated — a joined-up assessment by a specialist can help clarify whether a shared hormonal cause is responsible and guide appropriate management.

Diagnosis, Treatment Options and Outlook in the UK

Diagnosis begins with morning testosterone, LH, FSH, prolactin, and thyroid and liver function tests in primary care, with further investigations in secondary care; treatment targets the underlying cause and the overall outlook is generally positive.

The diagnostic workup for gynaecomastia in the UK typically begins in primary care. Your GP is likely to request an initial panel of blood tests, which usually includes:

• Serum total testosterone — measured in the morning (around 9 am) on two separate occasions to confirm any abnormality, alongside LH and FSH to assess gonadal function

• Prolactin — to screen for hyperprolactinaemia

• Thyroid function tests, liver function tests, and renal function — to identify systemic causes

Further investigations — including oestradiol, hCG, karyotyping (if Klinefelter syndrome is suspected), and scrotal ultrasound — are typically arranged in secondary care, guided by the findings of the initial assessment and clinical examination. A semen analysis is a standard first-line investigation for male fertility concerns and is usually arranged following GP referral in line with NICE NG156. Where breast malignancy is suspected, imaging is arranged via a specialist breast clinic as part of a formal triple assessment, rather than routinely in primary care.

Treatment depends entirely on the underlying cause:

• If a causative medication is identified, switching or stopping it (under medical supervision) may lead to resolution

• Hypogonadism: Testosterone replacement therapy (TRT) is not appropriate for men who are actively trying to conceive, as it suppresses the hypothalamic-pituitary-gonadal axis, can significantly impair spermatogenesis, and may worsen gynaecomastia through peripheral conversion to oestradiol. For men with hypogonadotrophic hypogonadism who wish to preserve or restore fertility, specialist-led treatment with gonadotrophins (hCG with or without FSH) is the preferred approach. If you are taking any testosterone product, refer to the patient information leaflet and report any suspected side effects via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk)

• Clomifene is sometimes used off-label in men under specialist supervision in specific clinical contexts; however, NICE NG156 does not recommend anti-oestrogens such as clomifene for the treatment of idiopathic male infertility, and it should not be used outside specialist guidance

• Hyperprolactinaemia caused by a pituitary adenoma is typically treated with dopamine agonists such as cabergoline, which can restore normal hormonal function and improve fertility. Suspected side effects should also be reported via the MHRA Yellow Card scheme

• Painful or distressing gynaecomastia in its early phase may be considered for treatment with tamoxifen under specialist advice; this is an off-label use and is not appropriate for self-medication

• Persistent gynaecomastia that does not resolve with medical management may be addressed surgically via subcutaneous mastectomy. NHS funding for this procedure varies by local Integrated Care Board (ICB) and may require an Individual Funding Request (IFR); your GP or specialist can advise on local criteria

The overall outlook is generally positive. Many cases of gynaecomastia resolve spontaneously or respond well to treatment of the underlying cause. When a shared hormonal disorder is identified and appropriately managed, improvements in both gynaecomastia and fertility outcomes are achievable. Men are encouraged to engage openly with their healthcare team, as early intervention typically leads to better results.

Further information: NHS: Gynaecomastia (enlarged male breast tissue) | NICE NG12: Suspected cancer — recognition and referral | NICE NG156: Fertility problems — assessment and treatment | NHS: Klinefelter syndrome | MHRA Yellow Card scheme

Frequently Asked Questions